In addition, we demonstrated that STAT3 knockdown decreased cell proliferation and increased imatinib sensitivity in KLC2-R312W and KLC2-L523I MT cells, similar to WT cells, highlighting the pivotal role of STAT3 in mediating drug resistance in CML cells. This evidence concerns the gene KLC2 and chronic myelogenous leukemia, BCR-ABL1 positive.